CA2376213A1 - Therapeutic agents - Google Patents

Therapeutic agents Download PDF

Info

Publication number: CA2376213A1
Authority: CA; Canada
Prior art keywords: formula; compound; lipase inhibitor; methyl; treatment
Prior art date: 1999-06-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002376213A

Other languages

English (en)

French (fr)

Inventor

Alan Martin Birch

David John Heal

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott GmbH and Co KG

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-24

Filing date

2000-06-16

Publication date

2001-01-04

2000-06-16 Application filed by Individual filed Critical Individual

2001-01-04 Publication of CA2376213A1 publication Critical patent/CA2376213A1/en

Status Abandoned legal-status Critical Current

Links

239000003814 drug Substances 0.000 title claims description 7
229940124597 therapeutic agent Drugs 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 91
229940086609 Lipase inhibitor Drugs 0.000 claims abstract description 48
238000011282 treatment Methods 0.000 claims abstract description 38
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 31
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims abstract description 26
150000003839 salts Chemical class 0.000 claims abstract description 26
208000008589 Obesity Diseases 0.000 claims abstract description 25
235000020824 obesity Nutrition 0.000 claims abstract description 25
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 22
229960001243 orlistat Drugs 0.000 claims abstract description 22
238000000034 method Methods 0.000 claims abstract description 19
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims description 22
238000002360 preparation method Methods 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 4
239000000203 mixture Substances 0.000 description 20
KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 18
-1 tetrahydrolipistatin Chemical compound 0.000 description 18
229910052739 hydrogen Inorganic materials 0.000 description 15
239000001257 hydrogen Substances 0.000 description 15
229960005303 sibutramine hydrochloride monohydrate Drugs 0.000 description 15
239000003826 tablet Substances 0.000 description 15
239000003981 vehicle Substances 0.000 description 14
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 12
229960004425 sibutramine Drugs 0.000 description 12
229910052760 oxygen Inorganic materials 0.000 description 11
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 10
208000016261 weight loss Diseases 0.000 description 10
230000004580 weight loss Effects 0.000 description 10
125000004432 carbon atom Chemical group C* 0.000 description 9
239000002775 capsule Substances 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
HFBHOAHFRNLZGN-LURJTMIESA-N (2s)-2-formamido-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC=O HFBHOAHFRNLZGN-LURJTMIESA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
125000004430 oxygen atom Chemical group O* 0.000 description 6
229940127470 Lipase Inhibitors Drugs 0.000 description 5
125000000217 alkyl group Chemical group 0.000 description 5
125000003118 aryl group Chemical group 0.000 description 5
230000037396 body weight Effects 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
239000008187 granular material Substances 0.000 description 5
150000002431 hydrogen Chemical class 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
229910052717 sulfur Inorganic materials 0.000 description 5
125000004434 sulfur atom Chemical group 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
230000037406 food intake Effects 0.000 description 4
235000009200 high fat diet Nutrition 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000000047 product Substances 0.000 description 4
239000000829 suppository Substances 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000002702 enteric coating Substances 0.000 description 3
238000009505 enteric coating Methods 0.000 description 3
235000012631 food intake Nutrition 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
150000004682 monohydrates Chemical class 0.000 description 3
210000000214 mouth Anatomy 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
229960003466 sibutramine hydrochloride Drugs 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
MENAYYMPBRSAAE-AWEZNQCLSA-N 3-[[5-[[(2s)-1-carboxy-3-oxopropan-2-yl]carbamoyl]pyridin-2-yl]methylsulfamoyl]benzoic acid Chemical compound N1=CC(C(=O)N[C@@H](CC(=O)O)C=O)=CC=C1CNS(=O)(=O)C1=CC=CC(C(O)=O)=C1 MENAYYMPBRSAAE-AWEZNQCLSA-N 0.000 description 2
208000032841 Bulimia Diseases 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
208000002705 Glucose Intolerance Diseases 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
235000019759 Maize starch Nutrition 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
108050006759 Pancreatic lipases Proteins 0.000 description 2
102000019280 Pancreatic lipases Human genes 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000002947 alkylene group Chemical group 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
125000005110 aryl thio group Chemical group 0.000 description 2
125000004104 aryloxy group Chemical group 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
238000001030 gas--liquid chromatography Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
229940116369 pancreatic lipase Drugs 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
201000009104 prediabetes syndrome Diseases 0.000 description 2
230000002265 prevention Effects 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000000926 separation method Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
239000011593 sulfur Chemical group 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
230000035924 thermogenesis Effects 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
WQSACWZKKZPCHN-CQSZACIVSA-N (1r)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1([C@H](N)CC(C)C)CCC1 WQSACWZKKZPCHN-CQSZACIVSA-N 0.000 description 1
PLXKZKLXYHLWHR-OAHLLOKOSA-N (1r)-1-[1-(4-chlorophenyl)cyclobutyl]-n,3-dimethylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1([C@@H](CC(C)C)NC)CCC1 PLXKZKLXYHLWHR-OAHLLOKOSA-N 0.000 description 1
WQSACWZKKZPCHN-AWEZNQCLSA-N (1s)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1([C@@H](N)CC(C)C)CCC1 WQSACWZKKZPCHN-AWEZNQCLSA-N 0.000 description 1
PLXKZKLXYHLWHR-HNNXBMFYSA-N (1s)-1-[1-(4-chlorophenyl)cyclobutyl]-n,3-dimethylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1([C@H](CC(C)C)NC)CCC1 PLXKZKLXYHLWHR-HNNXBMFYSA-N 0.000 description 1
XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
NEBHNFJAFFHYGN-BYPYZUCNSA-N (2s)-2-carbamoyl-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(N)=O)C(O)=O NEBHNFJAFFHYGN-BYPYZUCNSA-N 0.000 description 1
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
PLXKZKLXYHLWHR-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,3-dimethylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1(C(CC(C)C)NC)CCC1 PLXKZKLXYHLWHR-UHFFFAOYSA-N 0.000 description 1
RWRGOLQBUWFIQV-UHFFFAOYSA-N 3-(3-amino-3-oxopropyl)sulfanylpropanoic acid Chemical compound NC(=O)CCSCCC(O)=O RWRGOLQBUWFIQV-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
229940122200 5 Hydroxytryptamine uptake inhibitor Drugs 0.000 description 1
ODHCTXKNWHHXJC-GSVOUGTGSA-N 5-oxo-D-proline Chemical compound OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
206010004716 Binge eating Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102000013392 Carboxylesterase Human genes 0.000 description 1
108010051152 Carboxylesterase Proteins 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010019909 Hernia Diseases 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010033664 Panic attack Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
108010073771 Soybean Proteins Proteins 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
239000005864 Sulphur Chemical group 0.000 description 1
206010043118 Tardive Dyskinesia Diseases 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
LJMJTWHHROBQOE-DZUOILHNSA-N [(2s)-1-[(2s,3s)-3-ethyl-4-oxooxetan-2-yl]nonadecan-2-yl] (2s)-2-formamido-4-methylpentanoate Chemical compound CCCCCCCCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CC LJMJTWHHROBQOE-DZUOILHNSA-N 0.000 description 1
DMYQVZFQHRNQJD-KCHLEUMXSA-N [(2s)-1-[(2s,3s)-3-ethyl-4-oxooxetan-2-yl]nonadecan-2-yl] 1-carbamoylcyclohexane-1-carboxylate Chemical compound C([C@H](CCCCCCCCCCCCCCCCC)OC(=O)C1(CCCCC1)C(N)=O)[C@@H]1OC(=O)[C@H]1CC DMYQVZFQHRNQJD-KCHLEUMXSA-N 0.000 description 1
COGKGUUMTRBTTQ-QKDODKLFSA-N [(2s)-1-[(2s,3s)-3-ethyl-4-oxooxetan-2-yl]nonadecan-2-yl] 1-carbamoylcyclopentane-1-carboxylate Chemical compound C([C@H](CCCCCCCCCCCCCCCCC)OC(=O)C1(CCCC1)C(N)=O)[C@@H]1OC(=O)[C@H]1CC COGKGUUMTRBTTQ-QKDODKLFSA-N 0.000 description 1
JQSYIBJVIXNPLU-QORCZRPOSA-N [(2s)-1-[(2s,3s)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2s)-2-carbamoyl-3-methylbutanoate Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@@H](C(C)C)C(N)=O)C[C@@H]1OC(=O)[C@H]1CCCCCC JQSYIBJVIXNPLU-QORCZRPOSA-N 0.000 description 1
CLYUMKOZZIGLAV-GSDHBNRESA-N [(2s)-1-[(2s,3s)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] 1-carbamoylcyclohexane-1-carboxylate Chemical compound C([C@H](CCCCCCCCCCC)OC(=O)C1(CCCCC1)C(N)=O)[C@@H]1OC(=O)[C@H]1CCCCCC CLYUMKOZZIGLAV-GSDHBNRESA-N 0.000 description 1
ATSSPNQNBOHRKT-MCSJAMFESA-N [(2s)-1-[(2s,3s)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] 2-carbamoylhexanoate Chemical compound CCCCCCCCCCC[C@H](OC(=O)C(CCCC)C(N)=O)C[C@@H]1OC(=O)[C@H]1CCCCCC ATSSPNQNBOHRKT-MCSJAMFESA-N 0.000 description 1
PPWDAJPQZOLFFV-DRNWNIILSA-N [(2s)-1-[(2s,3s)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] 2-carbamoylpentanoate Chemical compound CCCCCCCCCCC[C@H](OC(=O)C(CCC)C(N)=O)C[C@@H]1OC(=O)[C@H]1CCCCCC PPWDAJPQZOLFFV-DRNWNIILSA-N 0.000 description 1
BFKWNORTGLXMDJ-CVRJERCRSA-N [(2s)-1-[(2s,3s)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] 3-amino-2-benzyl-3-oxopropanoate Chemical compound C([C@H](CCCCCCCCCCC)OC(=O)C(CC=1C=CC=CC=1)C(N)=O)[C@@H]1OC(=O)[C@H]1CCCCCC BFKWNORTGLXMDJ-CVRJERCRSA-N 0.000 description 1
229960002632 acarbose Drugs 0.000 description 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000012042 active reagent Substances 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
238000011914 asymmetric synthesis Methods 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical class O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
208000014679 binge eating disease Diseases 0.000 description 1
244000309464 bull Species 0.000 description 1
210000004900 c-terminal fragment Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
229950002397 cetilistat Drugs 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940099898 chlorophyllin Drugs 0.000 description 1
235000019805 chlorophyllin Nutrition 0.000 description 1
201000001883 cholelithiasis Diseases 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
125000004387 flavanoid group Chemical group 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
208000001130 gallstones Diseases 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
150000002332 glycine derivatives Chemical class 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
235000021374 legumes Nutrition 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229940040461 lipase Drugs 0.000 description 1
OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002175 menstrual effect Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000003801 milling Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
229940126569 noradrenaline reuptake inhibitor Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000012053 oil suspension Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
RQFZMIXBLJEUGS-UHFFFAOYSA-N panclicin-D Natural products CCCCCCCCCCC1C(CC(CCCCCCC)OC(=O)CNC=O)OC1=O RQFZMIXBLJEUGS-UHFFFAOYSA-N 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000019809 paraffin wax Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
208000000689 peptic esophagitis Diseases 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
229920002414 procyanidin Polymers 0.000 description 1
239000003380 propellant Substances 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000036186 satiety Effects 0.000 description 1
235000019627 satiety Nutrition 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
201000002859 sleep apnea Diseases 0.000 description 1
239000000779 smoke Substances 0.000 description 1
230000005586 smoking cessation Effects 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000019710 soybean protein Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
208000022170 stress incontinence Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
150000003648 triterpenes Chemical class 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000019195 vitamin supplement Nutrition 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000011680 zucker rat Methods 0.000 description 1
229930007845 β-thujaplicin Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Obesity (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Child & Adolescent Psychology (AREA)
Chemical Kinetics & Catalysis (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002376213A 1999-06-24 2000-06-16 Therapeutic agents Abandoned CA2376213A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9914742.3		1999-06-24
GBGB9914742.3A GB9914742D0 (en)	1999-06-24	1999-06-24	Therapeutic agents
PCT/EP2000/005544 WO2001000187A2 (en)	1999-06-24	2000-06-16	Pharmaceutical composition containing sibutramine and a lipase inhibitor

Publications (1)

Publication Number	Publication Date
CA2376213A1 true CA2376213A1 (en)	2001-01-04

Family

ID=10855953

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002376213A Abandoned CA2376213A1 (en)	1999-06-24	2000-06-16	Therapeutic agents

Country Status (20)

Country	Link
EP (1)	EP1189638A2 (cs)
JP (1)	JP2003503344A (cs)
KR (1)	KR20020012293A (cs)
CN (1)	CN1365287A (cs)
AU (1)	AU5815100A (cs)
BG (1)	BG106209A (cs)
BR (1)	BR0011884A (cs)
CA (1)	CA2376213A1 (cs)
CZ (1)	CZ20014614A3 (cs)
GB (1)	GB9914742D0 (cs)
HK (1)	HK1050476A1 (cs)
HU (1)	HUP0201880A3 (cs)
IL (1)	IL147078A0 (cs)
MX (1)	MXPA01013023A (cs)
NO (1)	NO20016301D0 (cs)
PL (1)	PL352387A1 (cs)
SK (1)	SK18822001A3 (cs)
TR (1)	TR200103704T2 (cs)
WO (1)	WO2001000187A2 (cs)
ZA (1)	ZA200110046B (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6399826B1 (en) *	1999-08-11	2002-06-04	Sepracor Inc.	Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US7089666B2 (en) *	2003-06-06	2006-08-15	The Regents Of The University Of California	Microfabricated vertical comb actuator using plastic deformation
CA2663254C (en)	2006-09-15	2016-04-19	Reviva Pharmaceuticals, Inc.	Synthesis, methods of using, and compositions of cycloalkylmethylamines
CN101890017A (zh) *	2009-05-22	2010-11-24	北京奥萨医药研究中心有限公司	含有西布曲明和他汀类降脂药物的药物组合物及其用途
WO2012003501A2 (en)	2010-07-02	2012-01-05	Reviva Pharmaceuticals, Inc.	Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US9238625B2 (en)	2011-12-30	2016-01-19	Reviva Pharmaceuticals, Inc.	Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

1999
- 1999-06-24 GB GBGB9914742.3A patent/GB9914742D0/en not_active Ceased
2000
- 2000-06-16 KR KR1020017016577A patent/KR20020012293A/ko not_active Ceased
- 2000-06-16 MX MXPA01013023A patent/MXPA01013023A/es unknown
- 2000-06-16 EP EP00943819A patent/EP1189638A2/en not_active Withdrawn
- 2000-06-16 CN CN00810544A patent/CN1365287A/zh active Pending
- 2000-06-16 CA CA002376213A patent/CA2376213A1/en not_active Abandoned
- 2000-06-16 TR TR2001/03704T patent/TR200103704T2/xx unknown
- 2000-06-16 IL IL14707800A patent/IL147078A0/xx unknown
- 2000-06-16 JP JP2001505897A patent/JP2003503344A/ja active Pending
- 2000-06-16 HU HU0201880A patent/HUP0201880A3/hu unknown
- 2000-06-16 SK SK1882-2001A patent/SK18822001A3/sk unknown
- 2000-06-16 AU AU58151/00A patent/AU5815100A/en not_active Abandoned
- 2000-06-16 WO PCT/EP2000/005544 patent/WO2001000187A2/en not_active Ceased
- 2000-06-16 CZ CZ20014614A patent/CZ20014614A3/cs unknown
- 2000-06-16 HK HK03101311.7A patent/HK1050476A1/zh unknown
- 2000-06-16 PL PL00352387A patent/PL352387A1/xx unknown
- 2000-06-16 BR BR0011884-2A patent/BR0011884A/pt not_active IP Right Cessation
2001
- 2001-12-06 ZA ZA200110046A patent/ZA200110046B/xx unknown
- 2001-12-11 BG BG06209A patent/BG106209A/xx unknown
- 2001-12-21 NO NO20016301A patent/NO20016301D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1189638A2 (en)	2002-03-27
AU5815100A (en)	2001-01-31
PL352387A1 (en)	2003-08-25
CZ20014614A3 (cs)	2004-02-18
NO20016301L (no)	2001-12-21
KR20020012293A (ko)	2002-02-15
BR0011884A (pt)	2003-08-12
BG106209A (en)	2002-09-30
CN1365287A (zh)	2002-08-21
HK1050476A1 (zh)	2003-06-27
WO2001000187A2 (en)	2001-01-04
NO20016301D0 (no)	2001-12-21
TR200103704T2 (tr)	2002-05-21
IL147078A0 (en)	2002-08-14
ZA200110046B (en)	2003-03-06
WO2001000187A3 (en)	2001-11-15
HUP0201880A2 (hu)	2002-12-28
MXPA01013023A (es)	2003-08-01
JP2003503344A (ja)	2003-01-28
SK18822001A3 (sk)	2003-04-01
GB9914742D0 (en)	1999-08-25
HUP0201880A3 (en)	2003-03-28

Legal Events

Date	Code	Title	Description
2001-12-12	EEER	Examination request
2005-06-16	FZDE	Discontinued

Publication	Publication Date	Title
US6403641B2 (en)	2002-06-11	Therapeutic agents
US6376552B1 (en)	2002-04-23	Treatment of gallstones
EP1187606A1 (en)	2002-03-20	Pharmaceutical composition containing sibutramine and orlistat
CA2376213A1 (en)	2001-01-04	Therapeutic agents
US6403650B1 (en)	2002-06-11	Treatment of pulmonary hypertension
RU2234917C2 (ru)	2004-08-27	Терапевтические средства
HK1034446B (en)	2004-11-19	Therapeutic agents
WO2000056316A1 (en)	2000-09-28	Treatment of gallstones
MXPA00006201A (en)	2001-06-26	Pharmaceutical composition containing sibutramine and orlistat